AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12369025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry measurement
Number of subjects: 803
Study 12369025 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 803
Study 10435729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg rhG-CSF/kg body weight plus 150 IU rhEpo/kg body weight
Number of subjects: 30
Study 10435729 — intervention group
Group type: COMPARATOR
Intervention: 5 microg rhG-CSF/kg body weight
Number of subjects: 30
Study 7607735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (nonselective agonist)
Number of subjects: 16
Study 7607735 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (endothelium-independent control)
Number of subjects: 16
Study 7607735 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (nonselective antagonist)
Number of subjects: 16
Study 7607735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1-selective antagonist)
Number of subjects: 16
Study 7607735 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-DX 116 (M2-selective antagonist)
Number of subjects: 16
Study 2132424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (BAY K 5552)
Number of subjects: 50
Study 2132424 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 50
Study 627337 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 3 X 25 mg orally for 5 days starting 2 days before menstruation
Number of subjects: 54
Study 627337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31607731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided microwave ablation
Number of subjects: 94
Study 31607731 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical excision
Number of subjects: 94
Study 29036816 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 71
Study 29036816 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education (CON)
Number of subjects: 71
Study 26125443 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CB)
Number of subjects: 268
Study 26125443 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 268
Study 26125443 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and mitomycin (CBM)
Number of subjects: 268
Study 26125443 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIRO-2 population
Number of subjects: 268
Study 23446090 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (66 to 532 mg)
Number of subjects: 823
Study 23446090 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl (75 to 200 mg)
Number of subjects: 823
Study 23446090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study 23446090 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Number of subjects: 823
Study 23446090 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl
Number of subjects: 823
Study 20854436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste (55 g daily, 16 mg lycopene)
Number of subjects: 20
Study 20854436 — intervention group
Group type: COMPARATOR
Intervention: Olive oil alone
Number of subjects: 20
Study 19176726 — intervention group
Group type: EXPERIMENTAL
Intervention: 25En% casein diet
Number of subjects: 24
Study 17185999 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.05‐0.6 mg/70 kg)
Number of subjects: 74
Study 17185999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.075‐0.5 mg/70 kg)
Number of subjects: 74
Study 15597592 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle (group F; n = 80)
Number of subjects: 147
Study 15597592 — intervention group
Group type: COMPARATOR
Intervention: Homograft (group H; n = 67)
Number of subjects: 147
Study 15597592 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle (group F)
Number of subjects: 147
Study 15597592 — intervention group
Group type: COMPARATOR
Intervention: Homograft (group H)
Number of subjects: 147
Study 15597592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 10937040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 14
Study 10937040 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 14
Study 9308614 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of lamotrigine 1 hour before spinal anesthesia
Number of subjects: 30
Study 8339576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 300
Study 8339576 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 300
Study 3555028 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin orally every 12 hours for two weeks
Number of subjects: 29
Study 3555028 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of ciprofloxacin orally every 12 hours for two weeks
Number of subjects: 29
Study 30513248 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trial (R-RCT)
Number of subjects: 0
Study 30513248 — intervention group
Group type: EXPERIMENTAL
Intervention: UCR clinical trials services
Number of subjects: 0
Study 30513248 — intervention group
Group type: EXPERIMENTAL
Intervention: UCR biobanking and biomarker analyses
Number of subjects: 0
Study 30513248 — intervention group
Group type: EXPERIMENTAL
Intervention: UCR quality registries
Number of subjects: 0
Study 30513248 — intervention group
Group type: EXPERIMENTAL
Intervention: UCR registry platform
Number of subjects: 0
Study 27566601 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional time discrimination task with emotional stimuli (neutral, positive, negative)
Number of subjects: 65
Study 27566601 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 65
Study 27218285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimpinella anisum‐based herbal medicine (Sinupim), 2 drops in each nostril every 12 hours for 4 weeks
Number of subjects: 48
Study 27218285 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasal spray, 2 puffs in each nostril every 12 hours for 4 weeks
Number of subjects: 48
Study 24691094 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg biweekly
Number of subjects: 614
Study 24691094 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 614
Study 24691094 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 614
Study 24691094 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 614
Study 24691094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 21166990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures with different attachment systems
Number of subjects: 106
Study 21166990 — intervention group
Group type: COMPARATOR
Intervention: Mandibular two-implant overdentures
Number of subjects: 106
Study 20647575 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative model between physicians and pharmacists for 9 months
Number of subjects: 27
Study 20647575 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative model between physicians and pharmacists for 24 months
Number of subjects: 27
Study 20647575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 17095130 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of hepatitis B vaccine
Number of subjects: 523
Study 17095130 — intervention group
Group type: COMPARATOR
Intervention: Three doses of hepatitis B vaccine
Number of subjects: 523
Study 16298778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and placebo light treatment
Number of subjects: 78
Study 16298778 — intervention group
Group type: EXPERIMENTAL
Intervention: Light treatment and placebo pill
Number of subjects: 78
Study 11991015 — intervention group
Group type: EXPERIMENTAL
Intervention: Shellyquine (plain formulation)
Number of subjects: 20
Study 11991015 — intervention group
Group type: COMPARATOR
Intervention: Dawaquin (sugar-coated formulation)
Number of subjects: 20
Study 12555338 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 51
Study 12555338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7759442 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (50% O2) for 30 min
Number of subjects: 9
Study 2339797 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-surface warming below the T10 dermatome (warmed group)
Number of subjects: 10
Study 2339797 — intervention group
Group type: COMPARATOR
Intervention: No extra warming (unwarmed group)
Number of subjects: 10
Study 2339797 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of warm lidocaine (40.6 +/‐ 0.7 degrees C)
Number of subjects: 10
Study 2339797 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of cold lidocaine (16.0 +/‐ 4.7 degrees C)
Number of subjects: 10
Study 2339797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall thermal comfort evaluation using a visual analog scale
Number of subjects: 10
Study 431801 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 45
Study 431801 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine response scale
Number of subjects: 45
Study 31774402 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified app intervention (n=141)
Number of subjects: 301
Study 31774402 — intervention group
Group type: COMPARATOR
Intervention: Nongamified app intervention (n=160)
Number of subjects: 301
Study 27680896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model without random effects for period-within-cluster
Number of subjects: 0
Study 27680896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model with random effects for cluster and period-within-cluster
Number of subjects: 0
Study 27680896 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised estimating equations
Number of subjects: 0
Study 27680896 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted cluster-level summary regression
Number of subjects: 0
Study 26109120 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow (HF) therapy
Number of subjects: 750
Study 26109120 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 750
Study 23689263 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Zn as zinc sulfate, daily for 21 days
Number of subjects: 282
Study 23689263 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 21 days
Number of subjects: 282
Study 21340616 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 18
Study 21340616 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 18
Study 21340616 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18
Study 21340616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19159453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100
Study 19159453 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 100
Study 19159453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Omega-3 fatty acids
Number of subjects: 100
Study 19159453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Aspirin)
Number of subjects: 100
Study 19159453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Omega-3 fatty acids)
Number of subjects: 100
Study 19159453 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Omega-3 fatty acids placebo
Number of subjects: 100
Study 19159453 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo and Omega-3 fatty acids
Number of subjects: 100
Study 17653751 — intervention group
Group type: EXPERIMENTAL
Intervention: ppV + ILM peeling
Number of subjects: 405
Study 17653751 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone (4 mg) injection
Number of subjects: 405
Study 17653751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 405
Study 15035674 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 21
Study 15035674 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 21
Study 11305510 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori CagA-positive strains
Number of subjects: 60
Study 9772056 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triple therapy (PCM): 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; followed by 40 mg pantoprazole o.d. until day 28.
Number of subjects: 286
Study 9772056 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (PC): 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days; followed by 40 mg pantoprazole o.d. until day 28.
Number of subjects: 286
Study 7530949 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision (TUIP)
Number of subjects: 765
Study 7530949 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 765
Study 3973786 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with rectally administered diazepam for 18 months, mean of five doses per child per year
Number of subjects: 289
Study 3973786 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with rectally administered diazepam for 18 months
Number of subjects: 289
Study 3973786 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis, diazepam rectally in the event of new seizures
Number of subjects: 289
Study 3973786 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 289
Study 31285835 — intervention group
Group type: EXPERIMENTAL
Intervention: RECALL intervention (6-week classroom-based intervention targeting working memory, attention, and language skills)
Number of subjects: 60
Study 31285835 — intervention group
Group type: COMPARATOR
Intervention: Active control (existing programme)
Number of subjects: 60
Study 31285835 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (education as usual)
Number of subjects: 60
Study 29912425 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFP at 14 g·steer‐1·d‐1
Number of subjects: 180
Study 29912425 — intervention group
Group type: COMPARATOR
Intervention: SCFP at 0 g·steer‐1·d‐1 (Control)
Number of subjects: 180
Study 29912425 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFP at 28 g·steer‐1·d‐1
Number of subjects: 180
Study 25787121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metformin gel with scaling and root planing (SRP)
Number of subjects: 65
Study 25787121 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel with scaling and root planing (SRP)
Number of subjects: 65
Study 25201648 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Better intervention (Cognitive Behavioural Therapy programme)
Number of subjects: 36
Study 25201648 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 36
Study 21911258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive oral S-adenosylmethionine (SAMe)
Number of subjects: 46
Study 21911258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20163389 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 0
Study 20163389 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent condition
Number of subjects: 0
Study 18043999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg
Number of subjects: 8
Study 18043999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 8
Study 18043999 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 8
Study 18043999 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 8
Study 18043999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic test
Number of subjects: 8
Study 17200303 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with plate fixation
Number of subjects: 132
Study 17200303 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 132
Study 15061293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oral ramosetron
Number of subjects: 109
Study 15061293 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg intravenous ramosetron
Number of subjects: 109
Study 10920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic source imaging (MSI) during printed word recognition task
Number of subjects: 10
Study 10920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic source imaging (MSI) during spoken word recognition task
Number of subjects: 10
Study 8970917 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (TG)
Number of subjects: 23
Study 8970917 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (CG)
Number of subjects: 23
Study 1452585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft placed beneath meshed, expanded split-thickness skin grafts (MESTSGs)
Number of subjects: 17
Study 1452585 — intervention group
Group type: COMPARATOR
Intervention: MESTSGs only (control)
Number of subjects: 17
Study 1452585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 17
Study 1452585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft and MESTSGs
Number of subjects: 17
Study 3881496 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 81
Study 3881496 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐76
Number of subjects: 81
Study 30661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) with supervised treadmill exercise
Number of subjects: 210
Study 30661439 — intervention group
Group type: COMPARATOR
Intervention: Placebo with supervised treadmill exercise
Number of subjects: 210
Study 30661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) with attention control
Number of subjects: 210
Study 30661439 — intervention group
Group type: COMPARATOR
Intervention: Placebo with attention control
Number of subjects: 210
Study 30661439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (both with GM-CSF and placebo)
Number of subjects: 210
Study 28054964 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D3
Number of subjects: 201
Study 28054964 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3
Number of subjects: 201
Study 26411666 — intervention group
Group type: EXPERIMENTAL
Intervention: C&R algorithm (Classification and Regression)
Number of subjects: 303
Study 26411666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Net algorithm
Number of subjects: 303
Study 26411666 — intervention group
Group type: EXPERIMENTAL
Intervention: C5.0, CHAID, C&R models
Number of subjects: 303
Study 26411666 — intervention group
Group type: EXPERIMENTAL
Intervention: C&R model
Number of subjects: 303
Study 24152567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily (Triple)
Number of subjects: 42
Study 24152567 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg daily (Double)
Number of subjects: 42
Study 21367347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 710
Study 21367347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 19011963 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Behavioral Interventions and Supports (PBIS)
Number of subjects: 2596
Study 17377212 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I, n = 18)
Number of subjects: 36
Study 17377212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with simvastatin, Group II, n = 18)
Number of subjects: 36
Study 14687744 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg combined with medroxyprogesterone acetate 5 mg (CEE/MPA, n=31)
Number of subjects: 95
Study 14687744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n=42)
Number of subjects: 95
Study 14687744 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 95
Study 11302565 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 19
Study 11302565 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 19
Study 9215327 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational/consultation intervention
Number of subjects: 446
Study 9215327 — intervention group
Group type: COMPARATOR
Intervention: Control home
Number of subjects: 446
Study 9215327 — intervention group
Group type: EXPERIMENTAL
Intervention: All three homes
Number of subjects: 446
Study 9215327 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 446
Study 8483562 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM (mitomycin 7‐8 mg/m2 i.v. every 6 weeks; mitoxantrone 7‐8 mg/m2 i.v. every 3 weeks; methotrexate 35 mg/m2 i.v. every 3 weeks)
Number of subjects: 347
Study 8483562 — intervention group
Group type: COMPARATOR
Intervention: VAC (vincristine 1.4 mg/m2 every 3 weeks, anthracycline 30 mg/m2 every 3 weeks, cyclophosphamide 400 mg/m2 every 3 weeks)
Number of subjects: 347
Study 8483562 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg orally, days 1‐14; methotrexate 35 mg/m2 i.v. days 1 and 8; 5‐fluorouracil 1 g i.v. days 1 and 8)
Number of subjects: 347
Study 2880718 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 68
Study 2880718 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 68
Study 29705473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique lessons
Number of subjects: 30
Study 29705473 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture sessions
Number of subjects: 30
Study 29705473 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30